^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/18/2022
Excerpt:
CLL/SLL without del(17p)/TP53 mutation...Preferred regimens...Zanubrutinib
